Fortress Biotech, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Accrued Liabilities and other Long-Term Liabilities (Tables)

Accrued Liabilities and other Long-Term Liabilities (Tables)

6 Months Ended

Jun. 30, 2019

Accrued Liabilities and other Long-Term Liabilities

Schedule of accrued expenses and other long-term liabilities

Accrued expenses and other long-term liabilities consisted of the following:


	June 30,		December
($ in thousands)	2019		31, 2018
	(Unaudited)
Accrued expenses:
Professional fees	$	1,051	$	1,434
Salaries, bonuses and related benefits		4,479		5,843
Research and development		3,527		3,805
Research and development - manufacturing		946		826
Research and development - clinical supplies		160		160
Research and development - license maintenance fees		409		519
Research and development - milestones		200		200
Dr. Falk Pharma milestone		—		300
Accrued royalties payable		1,641		1,108
Accrued coupon expense		981		838
Other		1,401		1,327
Total accrued expenses	$	14,795	$	16,360

Other long-term liabilities:
Deferred rent and long-term lease abandonment charge(1)		2,229		5,211
Total other long-term liabilities	$	2,229	$	5,211

Note 1: As of June 30, 2019, balance consists of deferred charges related to build-out of the New York facility, and as of December 31, 2018, balance consists of deferred rent and deferred build out charges.